{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-025891","form_type":"8-K","ticker":"CERS","cik":"0001020214","company_name":"CERUS CORP","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.126745+00:00","generated_at":"2026-06-05T03:19:52.639742+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cerus Q4 net loss narrows to $1.3M; achieves adj. EBITDA breakeven; reiterates FY2024 guidance","bullets":["Q4 net loss attributable to Cerus narrowed to $1.3M ($0.01/share) from $13.6M ($0.08) a year ago.","Q4 total revenue $53.3M (+4% YoY); product revenue $46.8M (+6% YoY), driven by North America platelet growth.","Achieved Q4 adjusted EBITDA breakeven at +$4.7M vs -$3.7M in Q4 2022.","Reiterated FY2024 product revenue guidance of $172-175M; INTERCEPT Fibrinogen Complex expected $8-10M.","Cash and investments $65.9M at Dec 31; net cash used in ops $43.2M for FY2023, up from $25.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-025891","json":"https://secwatch.observer/filing/0000950170-24-025891.json","markdown":"https://secwatch.observer/filing/0000950170-24-025891.md","text":"https://secwatch.observer/filing/0000950170-24-025891.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1020214/000095017024025891/0000950170-24-025891-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1020214/000095017024025891/cers-20240305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T03:19:52.639742+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5a80b20c60ea2af61c3ce874f506c2a98697b86d","claim":"CERUS CORP reported Fourth Quarter 2023 results: revenue $53,342, net income Net loss attributable to Cerus Corporation for the fourth quarter of 2023 was $1.3 million, EPS $0.01 per basic and diluted share.","evidence_excerpt":"Total Revenue $53,342 $51,321 $2,021 4% $186,797 $188,315 $(1,518) -1%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1020214/000095017024025891/0000950170-24-025891-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter 2023"},{"label":"Revenue","value":"$53,342"},{"label":"Net income","value":"Net loss attributable to Cerus Corporation for the fourth quarter of 2023 was $1.3 million"},{"label":"EPS","value":"$0.01 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"73259f6acee54e4d348c4821df748c96a9ae3d41","claim":"CERUS CORP reported Full-Year 2024 results: revenue $172-175 Million. Guidance reaffirmed.","evidence_excerpt":"The Company is reiterating its full-year 2024 annual product revenue guidance range of $172 million to $175 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1020214/000095017024025891/0000950170-24-025891-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full-Year 2024"},{"label":"Revenue","value":"$172-175 Million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"baf9b371b6cadfa1caf3374d0e435c498099708f","claim":"CERUS CORP reported Fourth Quarter and Full-Year 2023 results: revenue $53,342, net income Net loss attributable to Cerus Corporation for the fourth quarter of 2023 was $1.3 million, EPS $0.01 per basic and diluted share. Guidance reaffirmed.","evidence_excerpt":"% 2023 2022 $ % Product Revenue $46,768 $44,034 $2,734 6% $156,367 $162,048 $(5,681) -4% Government Contract Revenue 6,574 7,287 (713) -10% 30,430 26,267 4,163 16% Total Revenue $53,342 $51,321 $2,021 4% $186,797 $188,315 $(1,518) -1% • The Company is reiterating its full-year 2024 annual product revenue guidance range of $172 million to $175 million. Included in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1020214/000095017024025891/0000950170-24-025891-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter and Full-Year 2023"},{"label":"Revenue","value":"$53,342"},{"label":"Net income","value":"Net loss attributable to Cerus Corporation for the fourth quarter of 2023 was $1.3 million"},{"label":"EPS","value":"$0.01 per basic and diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}